Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
SOPHARMA AD hereby informs that from 10 February 2015 up to and including 13 February 2015 the Company bought 10 500 own shares representing 0.0080% of the share capital of the Company, at a total value of 37 792 BGN on the Bulgarian Stock Exchange, the average price per share was 3.599 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 136 521, representing 3.89% of the share capital of the Company.
The Board of Directors of Sopharma AD (the “Company”) hereby notifies that the Invitation to the Extraordinary Meeting of Shareholders of “Sopharma” AD, which will take place on 1 November 2012 at 11:00, and in the absence of a quorum – on 15 November 2012 at 11:00 in Sofia, 16 “Iliensko shose” Str., has been registered in the Commercial Register under number 20120925101646.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 13 September 2012 up to and including 19 September 2012 the Company bought 550 own shares representing 0.00042% of the share capital of the Company, to the total value of BGN 1330.00 on the Bulgarian Stock Exchange. The average price per share was BGN 2.418.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 13 September 2012 up to and including 19 September 2012 the Company bought 550 own shares representing 0.00042% of the share capital of the Company, to the total value of BGN 1330.00 on the Bulgarian Stock Exchange. The average price per share was BGN 2.418.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
Sopharma AD notifies that for January 2015 the Company recorded a decrease of sales revenues of 43% compared to the same month of 2014, including 11% increase of domestic sales and 61% decrease of export sales.
The volatility of the RUB caused us to undertake actions to adjust the prices for our main export market - Russia, which prevented us from exporting during the period. Our forecast is that this slow down in the beginning of the year will be compensated already in the first quarter.
SOPHARMA AD hereby informs that from 29 January 2015 up to and including 4 February 2015 the Company bought 3 200 own shares representing 0.0024% of the share capital of the Company, at a total value of 11 534.90 BGN on the Bulgarian Stock Exchange, the average price per share was 3.605 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 126 021, representing 3.88% of the share capital of the Company.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 20 September 2012 up to and including 26 September 2012 the Company bought 400 own shares representing 0.0003% of the share capital of the Company, to the total value of BGN 963.80 on the Bulgarian Stock Exchange. The average price per share was BGN 2.41.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
SOPHARMA AD hereby informs that from 10 February 2015 up to and including 13 February 2015 the Company bought 10 500 own shares representing 0.0080% of the share capital of the Company, at a total value of 37 792 BGN on the Bulgarian Stock Exchange, the average price per share was 3.599 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 136 521, representing 3.89% of the share capital of the Company.
SOPHARMA AD hereby informs that from 12 February 2015 up to and including 18 February 2015 the Company bought 7 150 own shares representing 0.0054% of the share capital of the Company, at a total value of 25 608.50 BGN on the Bulgarian Stock Exchange, the average price per share was 3.58 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 143 671, representing 3.90% of the share capital of the Company.
The Board of Directors hereby notifies that the transformation through merger of Bulgarian Rose – Sevtopolis AD in Sopharma AD has been registered with the Commercial Register with number 20150226134200.
The registered capital of Sopharma AD is 134 797 899 BGN.Sopharma AD is now undertaking all necessary actions for registration of the new issuance of 2 797 899 shares, with nominal value of 1.00 BGN with the Central Depository AD.
